Condition: Acute Myeloid Leukemia · Mixed Lineage Leukemia Gene Mutation · Refractory AML · Sponsor: Kura Oncology, Inc.
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion. The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.
This description comes directly from the study's public registry record.
Kura Medical Information · 844-KURAONC · medinfo@kuraoncology.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic - Phoenix | Phoenix, Arizona, United States | Recruiting |
| Moores UC San Diego Cancer Center | La Jolla, California, United States | Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| UCLA - Bowyer Oncology Center | Los Angeles, California, United States | Recruiting |
| UC Irvine Health Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, Connecticut, United States | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Emory Healthcare - The Emory Clinic | Atlanta, Georgia, United States | Recruiting |
| Georgia Cancer Center at Augusta University | Augusta, Georgia, United States | Recruiting |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago, Illinois, United States | Recruiting |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05735184